Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer
Table 3
DNA damage response-related parameters and associated Wilcoxon rank-sum tests in PBMCs from healthy volunteers and OC patients, sensitive or resistant to platinum therapy.